The German Joint Federal Committee (G-BA) approved two additional indications for application of positron emission tomography (PET) / computed tomography (CT) in head and neck area

16

Jun 2017

In 2006, the Institute for Quality and Efficiency in Health Care (IQWIG) was commissioned to perform evaluation of application positron emission tomography (PET) / computed tomography (CT) in patients with different diseases.

In 2011, IQWIG published final report for evaluation of PET/CT in patients with head and neck tumors where it was concluded that the benefit assessment could not be performed due to lack of evidence. Additionally, it was stated that comparative studies especially randomized controlled trials (RCTs) are needed to assess diagnostic quality of PET or PET/CT.

In 2016, the situation with evidence for the use of PET/CT in head and neck tumors changed. The reevaluation of evidence for this indication was performed and 3 RCTs were identified. Then Joint Federal Committee (G-BA) concluded that the PET/CT is, in certain cases, suitable for avoiding the invasive procedures of neck dissection and laryngoscopic biopsy that required general anesthesia and can lead to several complications.

In March 2017, G-BA approved two additional indications for application of PET/CT for management of neck and head tumors in hospital settings after reevaluation. Thus, PET/CT was considered to use within:

  • Deciding whether a neck dissection in patients with advanced head and neck tumors or with unknown primary thrombosis syndromes of the head and neck region should be performed
  • Deciding whether a laryngoscopic biopsy should be performed in the laryngeal carcinoma if a reasoned suspicion of a persistent disease or recurrence exists after completion of a curatively intended therapy

These two indications were added within amendment of the Directive for methods and examinations that are used in hospital settings. This decision entered into force after publication in the Federal Law Gazette (Bundesgesetzblatt) on 1st of June. Then the same amendment was performed in the Directive for methods of the contract medical care and this decision entered into force on 7th of June.

See full text documents in German for hospital settings here.

See full text documents in German for contract care here.

See press release in German here.

Subscribe to our biweekly newsletter not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

17

Mar 2022

On February 21, 2022, it was announced by the Ministry of Health that the public consultation regarding the Draft Order amending the Common Package of Benefits of the National Health System (SNS) was open. The amendments and clarifications are related to the fields of in-vitro diagnostics, ENT, pulmonary and airways, e-health, neurology, dental care, radiology, and enteral nutrition.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

24

Feb 2022

On January 18, 2022, the Ministry of Health has awarded the Framework Agreement for the acquisition of 81 linear accelerators included in the High-End Technology Equipment Investment Plan. Furthermore, the National Institute of Health Management (INGESA) has also initiated the processing of the Framework Agreement that will facilitate the acquisition of the equipment in the fields of interventional cardiology, interventional vascular radiology, interventional neurovascular, digital brachytherapy, computed tomography, magnetic resonance imaging, PET-CT, SPECT-CT.

Read more